Related by context. All words. (Click for frequent words.) 73 cell lymphoma MCL 64 relapsed mantle 62 refractory follicular 62 non Hodgkin lymphomas 62 undergoing hematopoietic stem 62 refractory indolent non 61 Diffuse Large B 61 small lymphocytic lymphoma 61 previously untreated follicular 61 CHOP chemotherapy 60 follicular B 60 Non Hodgkin 60 cyclophosphamide doxorubicin vincristine 59 radioimmunotherapeutic agent 59 multiple myeloma MM 59 Chronic lymphocytic leukemia CLL 59 CVP cyclophosphamide vincristine 59 Cutaneous T 58 Relapsed Refractory 58 systemic anaplastic large 58 follicular CD# positive 57 Ph + acute lymphoblastic 57 pediatric acute lymphoblastic 57 relapsed refractory aggressive 57 refractory chronic lymphocytic 57 relapsed MM 57 Personalized Immunotherapy 56 mitoxantrone plus 56 rituximab refractory follicular 56 demonstrated antitumor activity 56 prednisolone chemotherapy 56 CHOP cyclophosphamide doxorubicin vincristine 56 patients receiving myelosuppressive 56 follicular Non Hodgkin 56 Relapsed 55 Archexin 55 atypical hemolytic uremic syndrome 55 CLL SLL 55 CVP chemotherapy 55 relapsed acute lymphoblastic 55 milatuzumab 55 5 Fluorouracil 55 leukemia CLL 55 Non Hodgkin Lymphoma 55 motexafin gadolinium 55 Peginterferon alfa 2b 55 refractory diffuse 55 Non Hodgkin lymphoma 55 Imatinib mesylate 55 antigen CD# 55 DLBCL 55 Cell Lymphoma CTCL 55 Temodar ® 54 MGd 54 plus DOXIL 54 papillary renal cell carcinoma 54 gemcitabine Gemzar ® 54 CD# CD# 54 hA# 54 cell lymphoma CTCL 54 relapsed refractory 54 ibritumomab tiuxetan 54 colon carcinoma 54 urothelial 54 Cell Non Hodgkin 54 LymphoStat B belimumab 54 BN# [004] 54 Vidaza azacitidine 54 Ribavirin causes 54 Tyrosine Kinase Inhibitors 54 cutaneous T 54 recombinant erythropoietin 54 refractory colorectal cancer 54 baseline LDH 54 gallium nitrate 54 anthracycline derivative 54 Pathway Inhibitor 54 refractory acute myeloid 54 Panzem R NCD 54 Ofatumumab 54 FOLFOX chemotherapy 54 relapsed leukemia 54 Hodgkin lymphoma NHL 54 CML CP 54 5 fluorouracil leucovorin 53 pancreatic adenocarcinoma 53 indolent follicular non 53 imatinib Gleevec ® 53 Epratuzumab 53 SPRYCEL ® 53 non hodgkin lymphoma 53 KRAS mutant 53 CYT# potent vascular disrupting 53 relapsed Acute Myeloid 53 idebenone 53 indolent lymphoma 53 systemic ALCL 53 BARACLUDE ® 53 refractory cutaneous T 53 alkylating 53 cell lymphoma DLBCL 53 corticosteroid dexamethasone 53 Hodgkin lymphoma HL 53 antimitotic 53 chronic myeloid 53 cell lymphoma 53 SSc 53 cell lymphomas 53 induced anemia 53 lymphoma Hodgkin lymphoma 53 thalidomide Thalomid 53 Fludarabine 53 Treanda 53 lactate dehydrogenase LDH 53 lymphoid malignancies 53 Chronic Myeloid Leukemia CML 53 Romidepsin 53 Soft Tissue Sarcoma 53 Omacetaxine 53 relapsed multiple myeloma 53 farletuzumab 53 azacytidine 53 interleukin IL -# 53 Amgen Neulasta R 53 rituximab refractory 53 sarcomatoid 52 Chronic Lymphocytic Leukemia CLL 52 carcinoembryonic antigen 52 cell chronic lymphocytic 52 kidney urologic 52 novel VDA molecule 52 Letairis ambrisentan 52 lenalidomide Revlimid R 52 Myelodysplastic Syndrome MDS 52 Follicular 52 Non Hodgkins Lymphoma 52 Relapsed Refractory Aggressive 52 prednisone CHOP 52 imatinib Gleevec 52 FUSILEV enhances 52 antiproliferative effects 52 NMIBC 52 Apoptone 52 cytokine refractory 52 Gleevec imatinib mesylate 52 Cell Lymphoma 52 leukemia AML 52 targeted antifolate 52 dasatinib Sprycel 52 B lymphocyte 52 pancreatic colon 52 metaplasia 52 Pralatrexate 52 Evoltra ® 52 5q deletion 52 epithelioid 52 recurrent glioblastoma multiforme 52 Follicular Lymphoma 52 acute lymphoblastic 52 alkylating agent 52 Campath alemtuzumab 52 Interferon beta 52 irinotecan doxorubicin oxaliplatin paclitaxel 52 metastatic malignant 52 ER CHOP 52 chronic immune thrombocytopenic 52 lung pancreatic 52 antiangiogenic therapy 52 peripheral blood mononuclear 52 pegylated liposomal doxorubicin 52 MDS AML 52 ® lenalidomide 52 Annamycin 52 PI3K/Akt pathway inhibitor 52 immune modulating 52 castrate resistant 52 Cotara ® 52 lymphoid tissue 52 alefacept 52 Anthracycline 52 generation purine nucleoside 52 Ibritumomab Tiuxetan 52 docetaxel Taxotere ® 52 cisplatin resistant 52 Nilotinib 52 Rituxan rituximab 52 cytarabine daunorubicin 51 indolent NHL 51 Decitabine 51 cell acute lymphoblastic 51 Temsirolimus 51 cyclophosphamide chemotherapy 51 tumor xenograft models 51 humanised monoclonal antibody 51 ixabepilone 51 nucleotide analog 51 severe oral mucositis 51 ALK inhibitors 51 Forodesine 51 pleomorphic 51 Immunosuppressive 51 oligodendrogliomas 51 Hormone Refractory Prostate Cancer 51 elacytarabine 51 Rituxan MabThera 51 chronic lymphocytic leukemia CLL 51 Pemetrexed 51 targeted radiotherapeutic 51 protein tyrosine phosphatase 1B 51 Chronic Myeloid Leukemia 51 hypoxia inducible factor 51 adriamycin 51 cisplatin gemcitabine 51 PEGylated interferon 51 mycosis fungoides 51 Myelodysplastic Syndrome 51 refractory chronic myeloid 51 NSCL cancer 51 Mantle Cell Lymphoma 51 relapsing remitting MS RRMS 51 evaluating Prochymal 51 localized renal 51 essential thrombocythemia ET 51 CG# [003] 51 Chronic Myelogenous Leukemia CML 51 tumor metastases 51 Voreloxin 51 follicular NHL 51 blastic 51 chimeric monoclonal antibody 51 haematologic 51 TNF Tumor Necrosis Factor 51 Safinamide 51 metaglidasen 51 imatinib resistant 51 trastuzumab Herceptin R 51 idiopathic membranous nephropathy 51 hematopoietic cancers 51 Patients Receiving 51 Acute Myeloid Leukemia AML 51 Sudhir Agrawal D.Phil 51 allogeneic HSCT 51 acute myeloid 51 Glioblastoma Multiforme 51 Sipuleucel T 51 HSP# inhibitor 51 intravenous belinostat 51 YONDELIS 51 Pegylated 51 gastric adenocarcinoma 51 squamous cell carcinoma SCC 51 thetreatment 51 gemcitabine cisplatin 51 vinca alkaloid 51 CTAP# Capsules 51 Camptosar ® 51 Toxicities 51 PD LID 51 Pivotal Study 51 selective modulator 51 prostate cancer mCRPC 51 small molecule Hedgehog 51 IMiDs ® 51 myeloid metaplasia 51 stage IIIb 51 autoantibody positive 51 malignant pheochromocytoma 51 Vidaza ® 51 MabThera Rituxan 51 poly ADP ribose polymerase 51 commercialize deforolimus 51 cilengitide 51 temozolomide Temodar 50 idiopathic thrombocytopenic purpura 50 ® imatinib mesylate 50 aMCI precursor 50 busulfan 50 pomalidomide 50 Leukemia AML 50 5 FU leucovorin 50 XYOTAX TM 50 Vidofludimus 50 BRAF V#E 50 bortezomib Velcade R 50 Etanercept 50 Blinatumomab 50 Chronic lymphocytic leukemia 50 TNF blocker therapy 50 meropenem 50 ritonavir boosted 50 EGFr 50 CPOP R 50 PNP inhibitor 50 Arzerra ofatumumab 50 5 HT4 50 Acute myelogenous leukemia 50 metastatic pancreatic 50 Vincristine 50 pretransplant 50 PhG alpha 1 50 HGS ETR2 50 erythroid 50 adjuvant cisplatin 50 acute promyelocytic leukemia APL 50 immune modulator 50 Paraplatin ® 50 Fluorouracil 50 endometrial adenocarcinoma 50 castrate resistant prostate cancer 50 Platinol ® cisplatin 50 non metastatic resectable 50 Ceflatonin 50 Leukemias 50 Introgen ADVEXIN 50 haematological 50 monocytic 50 Platinol ® 50 ovarian carcinoma 50 OHR/AVR# 50 hypoxic tumor 50 Genentech Rituxan 50 tyrosine kinase inhibitor TKI 50 non resectable metastatic 50 oral clodronate 50 Targeted Therapy 50 Onco TCS 50 Orally administered 50 AEG# 50 docetaxel Taxotere R 50 gemcitabine carboplatin 50 radiotherapeutic 50 PSN# [001] 50 Gleevec resistant 50 Anaplastic large 50 fluorouracil leucovorin 50 FGFR3 50 AML acute myeloid 50 etoposide 50 non splenectomized 50 Gleevec imatinib 50 soluble tumor necrosis 50 Naive Patients 50 Advanced Renal Cell 50 esophageal candidiasis 50 myeloproliferative 50 CIMZIA R 50 liposomal doxorubicin 50 malignant ascites 50 FOLFOX6 chemotherapy regimen 50 rituximab Rituxan 50 mutated KRAS 50 histologies 50 cyclophosphamide doxorubicin 50 efaproxiral 50 YONDELIS R 50 2 methoxyestradiol 50 Pegylated Interferon 50 deoxy 50 fludarabine cyclophosphamide 50 MALT lymphoma 50 basal cell nevus syndrome 50 refractory metastatic 50 T1c 50 Multiple Myeloma MM 50 PEGylated anti 50 TACI Ig 50 lung carcinomas 50 Philadelphia Chromosome Positive 50 Plicera 50 Zybrestat 50 Folfox 50 alfa 2a 50 Dasatinib 50 Patients Treated With 50 lymphocytic leukemia 50 Clofarabine 50 Non Hodgkins lymphoma 50 AKT inhibitor 50 dosing cohort 50 Gemcitabine 50 follicular lymphoma FL 50 BCG refractory carcinoma 50 lymphomas 50 colorectal adenocarcinoma 50 Refractory Hodgkin Lymphoma 49 galiximab 49 precursor acute lymphoblastic 49 administered concomitantly 49 mapatumumab 49 epithelial tumors 49 sorafenib tablets 49 topically administered 49 rhIGFBP 3 49 Apolipoprotein B 49 Romiplostim 49 hypereosinophilic syndrome 49 ALK inhibitor 49 Novel Inhibitor 49 TREANDA 49 paclitaxel Taxol ® 49 Gastrointestinal Stromal Tumors 49 metastatic renal 49 oral antiviral 49 Leydig cell 49 steroid refractory ulcerative 49 denileukin diftitox 49 Fludara ® 49 B lymphocytes 49 metastatic colorectal carcinoma 49 cisplatin carboplatin 49 IRX 2 49 Follicular lymphoma 49 Panzem R 49 EGFR mutant 49 antibody MAb 49 prostate carcinoma 49 Relapsing Remitting Multiple Sclerosis 49 virus HCV protease inhibitor 49 relapsed acute myelogenous 49 leukemia CML 49 castration resistant 49 low dose cytarabine 49 PKC# 49 bladder carcinoma 49 diagnosed glioblastoma multiforme 49 forodesine 49 FLT3 ITD 49 oral anti arrhythmic 49 relapsed follicular 49 endothelin receptor 49 liposomal formulation 49 FOLFIRI alone 49 Xeloda ® 49 HER2 positive metastatic breast 49 relapsed indolent NHL 49 HDACi 49 deletion 5q 49 ofatumumab HuMax CD# 49 papillary RCC 49 Clindamycin 49 Chemoradiation 49 Angiotensin Converting Enzyme 49 urothelial carcinoma 49 Squalamine 49 achieved CCyR 49 antiestrogen therapy 49 Cytarabine 49 veltuzumab 49 rhIL 7 49 nonmetastatic 49 Cholangiocarcinoma 49 Inhaled nitric oxide 49 Temodar temozolomide 49 HGS ETR1 49 OMP #M# 49 Hematologic 49 blinatumomab 49 Cannabinor 49 hyperphenylalaninemia HPA due 49 Proxinium TM 49 Antitumor Activity 49 chronic idiopathic 49 luteinizing hormone releasing 49 gefitinib Iressa 49 receptor tyrosine kinase inhibitor 49 radiation sensitizer 49 Treanda bendamustine 49 oblimersen 49 Antiangiogenic 49 immune dysregulation 49 ACAPODENE TM 49 Waldenstrom macroglobulinemia 49 allograft rejection 49 refractory ovarian cancer 49 depsipeptide 49 Gleevec Glivec 49 mouse xenograft models 49 APOPTONE 49 p# MAP kinase inhibitor 49 psoriatic skin 49 GMX# 49 follicular lymphoma 49 CD8 + cytotoxic 49 refractory Hodgkin 49 gastrointestinal stromal tumors GISTs 49 cyclophosphamide FC 49 rheumatoid arthritis RA psoriatic 49 Muraglitazar 49 polyglutamate 49 androgen independent 49 Metastatic Colorectal Cancer 49 Myeloid 49 Wearing crimson 49 refractory acute lymphoblastic 49 erlotinib Tarceva ® 49 breast pancreatic 49 #ME# 49 Nucleoside 49 Phase #/#a trial 49 etanercept Enbrel 49 refractory NSCLC 49 oral prodrug 49 leukemia ALL 49 oral squamous cell 49 Metastatic Melanoma 49 HuMax R 49 Previously Treated 49 Clolar ® 49 Taxotere docetaxel 49 MYLOTARG 49 metastatic colorectal 49 non Hodgkins Lymphoma 49 fluoropyrimidine 49 FavId 49 Trastuzumab 49 MAGE A3 ASCI 49 superficial bladder cancer 49 ZACTIMA TM ZD# 49 doxorubicin cyclophosphamide 49 Xelox 49 bendamustine 49 ANCA associated 49 Aplidin 49 daily subcutaneous injections 49 ALB # 49 acute humoral rejection 49 anaplastic 49 MLL AF9 49 Randomized Phase 49 hematological malignancy 49 lumiliximab 49 miconazole Lauriad ® 49 severe neutropenia 49 dasatinib Sprycel ® 49 investigational monoclonal antibody 49 evaluating tivozanib 48 intratumoral 48 estramustine 48 Castration Resistant Prostate Cancer 48 Natalizumab 48 metastatic bladder 48 gemcitabine Gemzar 48 Azacitidine 48 cutaneous squamous cell carcinoma 48 carmustine 48 ISTODAX 48 myelodysplastic syndromes MDS 48 radiotherapy RT 48 transplantation HCT 48 Ozarelix 48 LHRH receptor positive 48 prokinetic agent 48 acute myelogenous leukemia AML 48 Vidaza R 48 non resectable 48 torezolid 48 SYN# 48 Rituximab 48 relapsed AML 48 Endometrial 48 totipotent 48 DOXIL ® 48 Cytoxan 48 Novartis Afinitor 48 mutated K ras 48 Pharmion Vidaza 48 systemic juvenile idiopathic 48 acute GvHD 48 Atypical Hemolytic Uremic Syndrome 48 enforcer Probert 48 Degarelix 48 cyclophosphamide methotrexate 48 Pertuzumab 48 Clusterin 48 anti angiogenic agents 48 hepatorenal syndrome 48 histologic subtype 48 MP4OX 48 Sanofi Aventis Taxotere 48 anthracycline taxane 48 proteasome inhibitor 48 AVASTIN 48 thrombin receptor 48 R bisoprolol Euthyrox 48 Ph + 48 5HT 48 Zarnestra 48 pegfilgrastim 48 Gemzar ® 48 Vicinium TM 48 cell malignancies 48 prostate carcinomas 48 BRAF mutations 48 xenograft models 48 lymphoma CTCL 48 dimensional conformal radiation 48 Retreatment 48 hormone refractory metastatic prostate 48 Fludara 48 Interferon Beta 48 nucleoside analog 48 Cancidas 48 effector T 48 Elotuzumab 48 lenalidomide Revlimid 48 tumoral 48 glutamyl 48 glucocerebrosidase 48 taxane refractory 48 LHRH agonists 48 mitomycin 48 myeloproliferative neoplasms MPNs 48 arthritis PsA 48 ara C 48 HLA DRB1 * 48 folinic acid 48 Pegloticase 48 TO AVOID PREGNANCY WHILE 48 antiproliferative 48 lymphoproliferative disorders 48 potent antiproliferative 48 Amrubicin 48 lenalidomide dexamethasone 48 Tarceva TM 48 radezolid 48 lymphoma subtypes 48 KRAS wild 48 beta 1a 48 Bosutinib 48 secondary hyperparathyroidism 48 immunomodulatory properties 48 superficial basal cell carcinoma 48 relapsed ovarian cancer 48 sunitinib Sutent ® 48 HNSCC 48 cytoreduction 48 Seliciclib 48 Luteinizing Hormone Releasing Hormone 48 factor alpha TNF 48 myeloablative 48 monoclonal antibody conjugated 48 cetuximab Erbitux R 48 Beta catenin pathway 48 Beta Amyloid 48 Advanced Melanoma 48 sodium glucose cotransporter 48 dacarbazine DTIC 48 diagnosed Ph + 48 IgG1 monoclonal antibody 48 olmesartan 48 octreotide implant 48 Non Hodgkin Lymphomas 48 Bezielle 48 Taxol ® 48 Sprycel dasatinib 48 erythropoietic 48 chemo immunotherapy 48 epigenetic therapies 48 Tasimelteon 48 baminercept 48 Doxil ® 48 metastatic carcinoma 48 thiazolides 48 Monoclonal antibody 48 mitoxantrone chemotherapy 48 patientswith 48 Advanced Solid Tumors 48 paclitaxel Taxol R 48 Chronic Hepatitis C 48 unresectable stage 48 Mg Uk 48 pDCs 48 systemic mastocytosis 48 Velcade bortezomib 48 HuMax CD4 48 inhalation powder 48 Acute myeloid leukemia AML 48 advanced metastatic renal 48 malignant lymphomas 48 advanced hepatocellular carcinoma 48 HCV Genotype 48 myelodysplastic myeloproliferative diseases 48 bortezomib Velcade 48 sJIA 48 tubulin polymerization 48 tigecycline 48 complement inhibitor eculizumab 48 syngeneic 48 autosomal dominant polycystic kidney 48 Acute myeloid leukemia 48 multipotent adult 48 follicular lymphomas 48 haematological cancers 48 EOquin TM 48 pulmonary metastasis 48 Aptivus ® 48 renal cell carcinomas 48 nonsmall cell lung cancer 48 lapatinib Tykerb 48 pentostatin 48 Cyclophosphamide 48 melphalan prednisone 48 Kenndal McArdle netted 48 demethylating agents 48 CDDO Im 48 sunitinib Sutent 48 D aspartate NMDA receptor 48 Tiuxetan 47 pulmonary metastases 47 Sezary syndrome 47 pouchitis 47 Janus kinase 47 fludarabine phosphate 47 recurrent malignant glioma 47 pan HDAC inhibitor 47 cytogenetic responses 47 Stage IIB 47 PEG IFN 47 recurrent glioblastoma 47 leukotriene receptor antagonist 47 dyskeratosis congenita 47 glycoprotein GP IIb IIIa 47 MabCampath 47 predictive biomarker 47 antithymocyte globulin 47 de novo kidney transplant 47 idiopathic thrombocytopenic purpura ITP 47 TRAIL R1 47 HQK 47 miconazole nitrate 47 ongoing Phase 1b 47 5-FU/LV 47 octreotide acetate 47 completely resected 47 EGFR mutation positive 47 G CSF 47 cytopenias 47 resistant hormone refractory 47 GSTP1 47 Cisplatin 47 thyroid carcinoma 47 Myelofibrosis 47 antiangiogenic agent 47 hoFH 47 CTAP# 47 fosbretabulin 47 osteosarcomas 47 Glioblastoma Multiforme GBM 47 zoledronate 47 histone deacetylase HDAC inhibitor 47 sorafenib Nexavar ® 47 vidofludimus 47 leukemic 47 metastatic lymph nodes 47 EGFR TKI 47 Squamous 47 subependymal giant cell 47 Neulasta ® 47 romidepsin 47 taxotere 47 neutropenic sepsis 47 idarubicin 47 Gemzar gemcitabine 47 piperacillin tazobactam 47 glioblastoma multiforme GBM 47 Sapacitabine 47 docetaxel chemotherapy 47 refractory acute promyelocytic 47 rituximab 47 malignant cancerous 47 IL# PE#QQR 47 overt nephropathy 47 sorafenib Nexavar R 47 sargramostim 47 Carboplatin 47 ZACTIMA 47 gastrointestinal stromal tumor 47 haematologic malignancies 47 trans retinoic acid 47 nilotinib Tasigna ® 47 visilizumab 47 Lenalidomide 47 non Hodgkin lymphoma 47 vascular disrupting agents 47 CLL 47 Anti TNF 47 KRAS status 47 RIS NASN ASN 47 SCCHN 47 cetuximab Erbitux 47 metastatic castrate resistant 47 administered subcutaneously 47 hepatic encephalopathy HE 47 fumarate 47 telaprevir dosed 47 renal anemia 47 Aflibercept 47 AML MDS 47 Avastin Tarceva 47 Relapsed Refractory Multiple Myeloma 47 hepatocellular carcinomas 47 tumors GIST 47 non Hodgkin Lymphoma 47 chemotherapy induced neutropenia 47 compound AEZS 47 Benlysta belimumab 47 eculizumab 47 Trandolapril 47 BCG refractory 47 metastatic renal cell 47 pancreatic prostate 47 seropositive patients 47 Pradefovir 47 panobinostat 47 BMS# 47 gastrointestinal stromal tumors 47 refractory CLL 47 urothelial cancer 47 peginterferon alfa 2b 47 pain palliation 47 cell carcinoma RCC 47 acute leukemias 47 Arranon 47 intranasal formulation 47 injected subcutaneously 47 bacillus Calmette Guerin 47 Riluzole 47 plus prednisone 47 paclitaxel Taxol 47 Oxycyte TM 47 DXL# 47 acute mania 47 chronic HCV 47 EOquin 47 systemic lupus erythematosus SLE 47 juvenile idiopathic arthritis JIA 47 malignant astrocytoma 47 Albuferon TM 47 Complicated Skin 47 gastrin analogue TT 47 Abiraterone acetate 47 azacitidine 47 biliary tract cancer 47 enzastaurin 47 T Cell Lymphoma 47 Zolinza 47 comparator arm 47 exocrine pancreatic insufficiency EPI 47 TAXOTERE R 47 PEGylated Fab fragment 47 radiolabeled antibody 47 progression TTP 47 endoplasmic reticulum stress 47 TEMODAL 47 HBeAg negative 47 immune globulin intravenous 47 lymphoid cells 47 MyVax R 47 leukaemias 47 TAXOTERE ® 47 ofatumumab 47 cediranib 47 acyclovir Lauriad R 47 doxorubicin Adriamycin 47 Thalomid thalidomide 47 recurrent glioblastoma multiforme GBM 47 ovarian lung 47 triglyceride lowering 47 recurrent metastatic 47 HCl capsules 47 EpCAM 47 underwent resection 47 Peginterferon Alfa 2a 47 Lubiprostone 47 pralatrexate 47 locoregional recurrence 47 Irinotecan 47 microtubule inhibitor 47 docetaxel Injection Concentrate 47 allogeneic bone marrow 47 sorafenib Nexavar 47 lymphocytic 47 NRTI resistance 47 immune thrombocytopenic purpura 47 hormonally sensitive 47 B Cell Lymphoma 47 Bleomycin 47 Novantrone 47 NR2B selective 47 myeloproliferative disorder 47 essential thrombocythemia 47 candesartan cilexetil 47 myelofibrosis polycythemia vera 47 concurrent chemoradiation 47 neoplastic 47 chronic myeloid leukemia CML 46 Leukine ® 46 Alocrest 46 mucinous 46 treatment naive genotype 46 renal carcinoma 46 recurrent glioma 46 medically inoperable 46 pancreatic islet cell 46 Acute lymphoblastic leukemia 46 ORENCIA R 46 cytokeratin 46 dormant spores 46 Ceflatonin R 46 Basal cell 46 ccRCC 46 Bendamustine 46 leukemia lymphoma multiple myeloma 46 malignant pancreatic 46 gastrointestinal stromal tumors GIST 46 IMPDH inhibitor 46 TTR amyloidosis 46 histological subtype 46 null responder 46 Thalomid ® 46 Azedra 46 interferon alfa 46 oropharyngeal candidiasis OPC 46 Pyridorin 46 signal transduction inhibitor 46 Lennox Gastaut Syndrome 46 HMG CoA reductase inhibitors 46 aspirin clopidogrel 46 VIDAZA 46 constipation predominant irritable bowel 46 Myozyme alglucosidase alfa 46 chronic lymphocytic 46 stage IIIB 46 toenail onychomycosis 46 macroglobulinemia 46 bleomycin 46 cetuximab Erbitux ® 46 PRTX 46 lymphoid 46 follicular non 46 8mg/kg 46 Targretin capsules 46 Taxotere R 46 Leucovorin 46 HRPC 46 BR.# 46 trabectedin 46 recurrent genital herpes 46 lupus nephritis 46 pancreatic colorectal 46 Acute Myeloid Leukaemia AML 46 peritoneal carcinomatosis 46 recombinant enzyme 46 pediatric malignancies 46 chronic HBV infection 46 Brentuximab Vedotin SGN 46 Glioblastoma multiforme GBM 46 alpha 2a 46 epithelial ovarian 46 BAY #-# 46 Bevacizumab Avastin 46 Malignant Melanoma 46 mitoxantrone 46 intra arterial chemotherapy 46 polycythemia vera essential thrombocythemia 46 KRAS mutations occur 46 pemphigus vulgaris 46 neurofibromas 46 dose cohort 46 oropharyngeal candidiasis 46 cholangiocarcinoma 46 INCB# [003] 46 Alemtuzumab 46 Diabetic Macular Edema DME 46 abacavir Ziagen 46 adrenocortical carcinoma 46 hematologic cancers 46 ErbB2 positive 46 glufosfamide 46 mRCC 46 metastatic gastric 46 CAELYX 46 pediatric Crohn disease 46 ductal adenocarcinoma 46 carcinoma mCRC 46 naïve HCV 46 DOXIL 46 conventional DMARDs 46 myeloproliferative diseases 46 Cloretazine 46 allogeneic stem cell 46 bexarotene 46 Reovirus 46 lymphocytosis 46 Peginterferon 46 refractory CML 46 elotuzumab 46 ceftazidime 46 tumor malignancies